The Panel on Antiretroviral Guidelines for Adults and Adolescents (the Panel) has updated the Guidelines for Use of Antiretrovir

View as a webpage  /  Share March 23, 2023 Updates to the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV The Panel on Antiretroviral Guidelines for Adults and Adolescents (the Panel) updated the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Highlights from the updated sections are summarized below.  Lenacapavir, a first-in-class HIV capsid inhibitor, was approved by the U.S. Food and Drug Administration in December 2022 to be used in combination with other antiretroviral (ARV) drugs for the treatment of heavily treatment-experienced adults with multidrug-resistant HIV-1 infection. In this update to the guidelines, the following sections are revised to incorporate information regarding the use of lenacapavir: Drug-Resistance Testing Virologic Failure Hepatitis C Virus/HIV Coinfection Adverse Effects of Antiretroviral Agents Cost Considerations and Antiretroviral Therapy Drug–Drug Interactions Overview Table 24g—a new table with guidance on drug–drug interactions between lenacapavir and other drugs (including ARV agents) Appendix B, Table 11. Characteristics of the Capsid Inhibitor—a new table on the characteristics of lenacapavir The Financial Disclosure has been updated to include the Panel members' financial disclosure for companies related to HIV treatment or diagnostics for the period of March 1, 2022, to February 28, 2023. Clinicalinfo welcomes your feedback on the latest revisions to the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Please send your comments with the subject line "Adult and Adolescent ARV Guidelines" to HIVinfo@NIH.gov by April 14, 2023. Stay Connected with HIVinfo:       SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

 

---

You are subscribed as myhcistech.healthnews360@blogger.com.  Update your subscriptions, modify your password or email address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your email address to log in. If you have questions or problems with the subscription service, please visit the GovDelivery Subscriber Help Center at https://insights.govdelivery.com/Communications/Subscriber_Help_Center.

This service is provided in collaboration with NIH's Office of AIDS Research and HHS Office of Infectious Disease and HIV/AIDS Policy/HIV.gov.

---

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: HIVinfo · 8600 Rockville Pike · Bethesda, MD 20894 · 888-346-3656